Fred Knoll may be interested in another unique biotech play, based on his involvement in a fund called Europa International Inc. With Knoll Capital Management as an advisor, Europa International acquired a shell holding company that reverse merged with a biotech company called AtheroNova Inc. (OTCQB: AHRO) to take it public. The stock has since been quietly trading – much like Medivation – whilst pursuing clinical trials. If Mr. Knoll is right about this company, as he was with Medivation, the stock could see significant upside from these levels.
AtheroNova’s most advanced candidate, AHRO-001, is a proprietary compound administered via tablet that dissolves plaque within arterial walls, through a process known as delipidization, and then safely remove it from the body using a natural metabolic process. With the statin industry producing many blockbuster drugs – including Pfizer Inc.’s (NYSE: PFE) Lipitor® as the best selling drug in history – there’s clear potential in a safer and more efficacious solution that gets to the root of the problem rather than simply addressing a symptom like LDL cholesterol levels.
To see early anecdotal evidence of efficacy, check out the following video: